Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Deploying Permaseal Stories

2012-10-22 07:30:02

BETHLEHEM, Pa., Oct. 22, 2012 /PRNewswire/ -- Micro Interventional Devices, Inc.(TM) (MID), an emerging cardiovascular medical device company, announced today that the first patient has been treated using its self-sealing, cardiac access and closure technology, Permaseal(TM). The patient is the first to be enrolled in the company's STASIS clinical trial that has commenced in Europe. The first STASIS case was performed by Principal Investigator Professor Dr. med. Rudiger Lange, Director of...